Allan joined Sygnature Discovery in February 2019 as Vice President of Oncology Drug Discovery, delivering broad scientific oversight and mentorship of all Sygnature’s oncology projects. With 25+ years’ experience in medicinal chemistry and drug discovery, he has actively participated in almost 60 drug discovery projects, resulting in the delivery of fifteen pre-clinical candidates of which ten have entered human clinical trials. He led the chemistry teams which developed the first cell-active inhibitors of the DNA repair protein PARG, now in Phase I trials with Ideaya Biosciences and the first reversible, selective inhibitors of the epigenetic enzyme DNMT-1, in collaboration with GSK.